Expression Profile of Endoglin in Different Grades of Endometrial Cancer

被引:14
|
作者
Oplawski, Marcin [1 ,2 ]
Dziobek, Konrad [2 ]
Adwent, Iwona [3 ]
Dftbru, Dariusz [3 ]
Grabarek, Beniamin [1 ]
Zmarzly, Nikola [1 ]
Plewka, Andrzej [1 ,4 ]
Boron, Dariusz [2 ,3 ,5 ]
机构
[1] Med Univ Silesia, Sch Pharm, Dept Mol Biol, Div Lab Med Sosnowiec, Sosnowiec, Poland
[2] Ludwik Rydygier Mem Specialist Hosp, Dept Gynecol & Obstet Gynecol Oncol, Krakow, Poland
[3] Opole Med High Sch, Dept Midwifery, Opole, Poland
[4] Publ Higher Med Profess Sch Opole, Fac Hlth Sci, Opole, Poland
[5] Med Univ Silesia, Sch Med, Dept Histol & Embryol, Div Dent, Zabrze, Poland
关键词
Endometrial cancer; endoglin; angiogenesis; molecular marker; vascular endothelium; immunohistochemistry; ENDOTHELIAL GROWTH-FACTOR; TGF-BETA CORECEPTOR; PROGNOSTIC MARKERS; CD105; EXPRESSION; ANGIOGENESIS; CARCINOMA; VASCULATURE; METASTASIS; PREDICTOR; DIAGNOSIS;
D O I
10.2174/1389201020666181127152605
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Endoglin is a marker of active, proliferating endothelial cells of blood vessels. In many cancers, it is present in both peripheral vessels and vessels located inside the tumor. Endoglin is more specific and sensitive compared to other tumor angiogenesis markers. It is suggested that endoglin can be considered a reliable marker of disease outcome. Objective: The aim of the study was to assess the expression of endoglin and to determine its potential usefulness as a complementary molecular marker of endometrial cancer. Method: The study included 60 women who underwent hysterectomy: 45 with endometrioid endometrial cancer (study group) and 15 without neoplastic changes (control group). The study group was further divided according to the degree of histological differentiation: G1, 17; G2, 15; and G3, 13. The expression of endoglin was determined immunohistochemically with mouse anti-Endoglin monoclonal antibody. The obtained reactions were evaluated using light microscopy. Results: Analysis of endoglin expression in endothelium showed that it reached 145% of the control. In G2, we observed that the endoglin level decreased and was similar to the control, while in G3 it increased and was even higher than in G1. In cancer cells, endoglin expression increased with the grade of endometrial cancer. Conclusion: Endoglin can be considered a valuable complementary molecular marker, allowing to visualize the advancement of the cancer process, including endometrial cancer.
引用
收藏
页码:990 / 995
页数:6
相关论文
共 50 条
  • [1] Expression of Endoglin in Primary Endometrial Cancer
    Zakrzewski, Piotr K.
    Cygankiewicz, Adam I.
    Mokrosinski, Jacek
    Nowacka-Zawisza, Maria
    Semczuk, Andrzej
    Rechberger, Tomasz
    Krajewska, Wanda M.
    ONCOLOGY, 2011, 81 (3-4) : 243 - 250
  • [2] Variances in the Level of COX-2 and iNOS in Different Grades of Endometrial Cancer
    Oplawski, Marcin
    Dziobek, Konrad
    Zmarzly, Nikola
    Grabarek, Beniamin O.
    Kielbasinski, Robert
    Kieszkowski, Przemyslaw
    Januszyk, Piotr
    Talkowski, Karol
    Schweizer, Michal
    Kras, Piotr
    Plewka, Andrzej
    Boron, Dariusz
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2020, 21 (01) : 52 - 59
  • [3] Endoglin (CD105) expression in endometrial carcinoma
    Saad, RS
    Jasnosz, KM
    Tung, MY
    Silverman, JF
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2003, 22 (03) : 248 - 253
  • [4] Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer
    Dziobck, Konrad
    Oplawski, Marcin
    Grabarek, Benjamin Oskar
    Zmarzly, Nikola
    Tomala, Barbara
    Halski, Tomasz
    Lesniak, Ewa
    Januszyk, Krzysztof
    Brus, Ryszard
    Kielbasinski, Robert
    Boron, Dariusz
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2019, 20 (11) : 955 - 963
  • [5] Expression Profile of VEGF-C, VEGF-D, and VEGFR-3 in Different Grades of Endometrial Cancer
    Oplawski, Marcin
    Dziobek, Konrad
    Zmarzly, Nikola
    Grabarek, Beniamin
    Halski, Tomasz
    Januszyk, Piotr
    Kus-Kierach, Agnieszka
    Adwent, Iwona
    Dabrus, Dariusz
    Kielbasinski, Kamil
    Boron, Dariusz
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2019, 20 (12) : 1004 - 1010
  • [6] The expression and characterization of endoglin in uterine leiomyosarcoma
    Mitsui, Hiroko
    Shibata, Kiyosumi
    Mano, Yukio
    Suzuki, Shiro
    Umezu, Tomokazu
    Mizuno, Mika
    Yamamoto, Eiko
    Kajiyama, Hiroaki
    Kotani, Tomomi
    Senga, Takeshi
    Kikkawa, Fumitaka
    CLINICAL & EXPERIMENTAL METASTASIS, 2013, 30 (06) : 731 - 740
  • [7] Endoglin-Targeted Cancer Therapy
    Seon, Ben K.
    Haba, Akinao
    Matsuno, Fumihiko
    Takahashi, Norihiko
    Tsujie, Masanori
    She, Xinwei
    Harada, Naoko
    Uneda, Shima
    Tsujie, Tomoko
    Toi, Hirofumi
    Tsai, Hilda
    Haruta, Yuro
    CURRENT DRUG DELIVERY, 2011, 8 (01) : 135 - 143
  • [8] Identification of a gene expression profile associated with the regulation of angiogenesis in endometrial cancer
    Oplawski, Marcin
    Michalski, Mateusz
    Witek, Andrzej
    Michalski, Bogdan
    Zmarzly, Nikola
    Jeda-Golonka, Agnieszka
    Styblinska, Maria
    Gola, Joanna
    Kasprzyk-Zyszczynska, Malgorzata
    Mazurek, Urszula
    Plewka, Andrzej
    MOLECULAR MEDICINE REPORTS, 2017, 16 (03) : 2547 - 2555
  • [9] Overexpression of endoglin (CD105) is associated with recurrence in radically resected gastric cancer
    Koyama, Yoshihisa
    Okayama, Hirokazu
    Kumamoto, Kensuke
    Saito, Katsuharu
    Nakamura, Izumi
    Ohki, Shinji
    Takenoshita, Seiichi
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2010, 1 (04) : 627 - 633
  • [10] Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma
    Saarelainen, Sami K.
    Staff, Synnove
    Peltonen, Nina
    Lehtimaki, Terho
    Isola, Jorma
    Kujala, Paula M.
    Vuento, Maarit H.
    Maenpaa, Johanna U.
    TUMOR BIOLOGY, 2014, 35 (05) : 4651 - 4657